Twitxy Saved

Alex Rampotas

Verified account This account is verified. Learn more

@ARampotas

Haematologist | Developed the first CAR-T therapy for Myelofibrosis | @uclcancer Roddie/Pule lab #CART #MPN 🇬🇷🇬🇧 |Support by @BloodCancer_Res & @the_MRC
UCL Cancer Institute, UK scholar.google.com/scholar?hl=en&… Joined August 2018
1.5K Following 1.9K Followers 3.4K Posts

Latest posts 5

Pinned post

Alex Rampotas Verified account @ARampotas
1/ 🧵 So delighted to share our new paper, out today in Science Translational Medicine @ScienceTM. We built a CAR-T cell therapy that selectively depletes the disease-driving mutant calreticulin (mutCALR) cells in myelofibrosis — while sparing healthy blood stem cells👇

science.org/doi/10.1126/sc…
www.science.org CAR T cell therapy selectively depletes disease-driving mutant calreticulin cells in xenotranspla... A CALR mutant–targeted CAR T cell therapy selectively depletes mutant CALR+ cancer stem cells in vivo and in fibrotic human bone marrow organoids.
12 replies 25 reposts 119 likes 12K views View on X
Alex Rampotas Verified account @ARampotas
1/ Et tu, CD70?

Very pleased to commented in @BloodJournal with Claire Roddie, on Araujo-Ayala et al — how a molecule built to give T cells a brief, focused boost gets hijacked by follicular lymphoma into a permanent signal that wears them out. 🧵 ashpublications.org/blood/article/…
ashpublications.org Et tu, CD70? When friend turns foe for follicular lymphoma In this issue of Blood, Araujo-Ayala et al1 take a stab at dissecting the friend-foe dichotomy, thereby identifying CD70 as a biomarker of relapse risk in